Close Menu

Big Deal?

After receiving a promotional email from Elsevier, DrugMonkey considers what constitutes a noteworthy change in a journal's impact factor at his blog this week. The email, he says, advertises that one of the publisher's many titles saw a 0.336 boost in its impact factor from 2010 to 2011.

"Is this a significant difference? Who gives a hoot if the IF [impact factor] goes up by 0.336?" DrugMonkey asks. "Is this in any way meaningful?"

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.